Foghorn Therapeutics
Richard Caldwell is an experienced scientist specializing in immunology, immuno-oncology, and oncology research. Currently serving as Principal Scientist at Foghorn Therapeutics Inc. since September 2021, Richard previously held roles as Senior Scientist at EMD Serono, Inc. from May 2013 to September 2021, and contributed as a Scientist at GSK and Associate Researcher at Biogen. Richard's foundational work includes roles such as Senior Research Associate at GSK focusing on epigenetic modulation and Associate Scientist working on metabolic disease projects. Richard holds a Master of Science in Organic Chemistry from Lehigh University and dual Bachelor's degrees in Chemistry and Biochemistry from North Carolina State University.
This person is not in any teams
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.